vs

Side-by-side financial comparison of FTAI Infrastructure Inc. (FIP) and Mirum Pharmaceuticals, Inc. (MIRM). Click either name above to swap in a different company.

Mirum Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($148.9M vs $143.5M, roughly 1.0× FTAI Infrastructure Inc.). Mirum Pharmaceuticals, Inc. runs the higher net margin — -3.8% vs -68.1%, a 64.2% gap on every dollar of revenue. On growth, FTAI Infrastructure Inc. posted the faster year-over-year revenue change (77.7% vs 49.8%). Mirum Pharmaceuticals, Inc. produced more free cash flow last quarter ($5.5M vs $-68.6M). Over the past eight quarters, Mirum Pharmaceuticals, Inc.'s revenue compounded faster (46.7% CAGR vs 31.9%).

FTAI Infrastructure Inc. owns, operates and invests in high-quality critical infrastructure assets across core sectors including transportation logistics, midstream energy, and power generation. It primarily serves North American markets, focusing on assets with stable long-term cash flows, contracted revenue streams, and strong market positions to deliver sustainable returns for stakeholders.

Mirum Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies for patients with rare, debilitating liver diseases that have high unmet medical needs, serving both pediatric and adult patient groups across North America, Europe and other global regions.

FIP vs MIRM — Head-to-Head

Bigger by revenue
MIRM
MIRM
1.0× larger
MIRM
$148.9M
$143.5M
FIP
Growing faster (revenue YoY)
FIP
FIP
+27.9% gap
FIP
77.7%
49.8%
MIRM
Higher net margin
MIRM
MIRM
64.2% more per $
MIRM
-3.8%
-68.1%
FIP
More free cash flow
MIRM
MIRM
$74.1M more FCF
MIRM
$5.5M
$-68.6M
FIP
Faster 2-yr revenue CAGR
MIRM
MIRM
Annualised
MIRM
46.7%
31.9%
FIP

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FIP
FIP
MIRM
MIRM
Revenue
$143.5M
$148.9M
Net Profit
$-97.7M
$-5.7M
Gross Margin
Operating Margin
-45.7%
-3.1%
Net Margin
-68.1%
-3.8%
Revenue YoY
77.7%
49.8%
Net Profit YoY
21.6%
75.9%
EPS (diluted)
$-1.04
$-0.10

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FIP
FIP
MIRM
MIRM
Q4 25
$143.5M
$148.9M
Q3 25
$140.6M
$133.0M
Q2 25
$122.3M
$127.8M
Q1 25
$96.2M
$111.6M
Q4 24
$80.8M
$99.4M
Q3 24
$83.3M
$90.4M
Q2 24
$84.9M
$77.9M
Q1 24
$82.5M
$69.2M
Net Profit
FIP
FIP
MIRM
MIRM
Q4 25
$-97.7M
$-5.7M
Q3 25
$-104.5M
$2.9M
Q2 25
$-70.0M
$-5.9M
Q1 25
$120.2M
$-14.7M
Q4 24
$-124.7M
$-23.8M
Q3 24
$-43.0M
$-14.2M
Q2 24
$-48.1M
$-24.6M
Q1 24
$-50.3M
$-25.3M
Operating Margin
FIP
FIP
MIRM
MIRM
Q4 25
-45.7%
-3.1%
Q3 25
-70.8%
2.0%
Q2 25
-56.4%
-3.9%
Q1 25
81.8%
-13.6%
Q4 24
-152.7%
-24.4%
Q3 24
-51.7%
-14.0%
Q2 24
-56.4%
-31.1%
Q1 24
-58.8%
-38.2%
Net Margin
FIP
FIP
MIRM
MIRM
Q4 25
-68.1%
-3.8%
Q3 25
-74.4%
2.2%
Q2 25
-57.2%
-4.6%
Q1 25
125.0%
-13.2%
Q4 24
-154.4%
-23.9%
Q3 24
-51.6%
-15.8%
Q2 24
-56.7%
-31.6%
Q1 24
-60.9%
-36.5%
EPS (diluted)
FIP
FIP
MIRM
MIRM
Q4 25
$-1.04
$-0.10
Q3 25
$-1.38
$0.05
Q2 25
$-0.73
$-0.12
Q1 25
$0.89
$-0.30
Q4 24
$-1.21
$-0.49
Q3 24
$-0.45
$-0.30
Q2 24
$-0.52
$-0.52
Q1 24
$-0.54
$-0.54

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FIP
FIP
MIRM
MIRM
Cash + ST InvestmentsLiquidity on hand
$57.4M
$383.3M
Total DebtLower is stronger
$3.8B
Stockholders' EquityBook value
$21.3M
$314.7M
Total Assets
$5.7B
$842.8M
Debt / EquityLower = less leverage
176.99×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FIP
FIP
MIRM
MIRM
Q4 25
$57.4M
$383.3M
Q3 25
$34.7M
$375.5M
Q2 25
$33.6M
$304.6M
Q1 25
$26.3M
$277.7M
Q4 24
$27.8M
$280.3M
Q3 24
$20.3M
$284.4M
Q2 24
$33.1M
$278.4M
Q1 24
$23.0M
$302.8M
Total Debt
FIP
FIP
MIRM
MIRM
Q4 25
$3.8B
Q3 25
$3.7B
Q2 25
$3.1B
Q1 25
$2.8B
Q4 24
$1.6B
Q3 24
$1.5B
Q2 24
$1.6B
Q1 24
$1.3B
Stockholders' Equity
FIP
FIP
MIRM
MIRM
Q4 25
$21.3M
$314.7M
Q3 25
$181.1M
$292.0M
Q2 25
$375.5M
$255.2M
Q1 25
$476.2M
$233.3M
Q4 24
$202.7M
$225.6M
Q3 24
$370.8M
$232.0M
Q2 24
$394.8M
$229.0M
Q1 24
$402.5M
$234.6M
Total Assets
FIP
FIP
MIRM
MIRM
Q4 25
$5.7B
$842.8M
Q3 25
$5.5B
$785.1M
Q2 25
$4.4B
$725.8M
Q1 25
$4.1B
$690.2M
Q4 24
$2.4B
$670.8M
Q3 24
$2.4B
$667.9M
Q2 24
$2.5B
$660.8M
Q1 24
$2.3B
$652.0M
Debt / Equity
FIP
FIP
MIRM
MIRM
Q4 25
176.99×
Q3 25
20.59×
Q2 25
8.21×
Q1 25
5.79×
Q4 24
7.84×
Q3 24
4.14×
Q2 24
3.94×
Q1 24
3.34×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FIP
FIP
MIRM
MIRM
Operating Cash FlowLast quarter
$-2.8M
$6.1M
Free Cash FlowOCF − Capex
$-68.6M
$5.5M
FCF MarginFCF / Revenue
-47.8%
3.7%
Capex IntensityCapex / Revenue
45.9%
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-398.5M
$54.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FIP
FIP
MIRM
MIRM
Q4 25
$-2.8M
$6.1M
Q3 25
$-24.4M
$39.7M
Q2 25
$-5.2M
$12.0M
Q1 25
$-85.7M
$-2.0M
Q4 24
$-8.1M
$-5.1M
Q3 24
$14.2M
$4.0M
Q2 24
$-17.6M
$-3.8M
Q1 24
$-3.9M
$15.2M
Free Cash Flow
FIP
FIP
MIRM
MIRM
Q4 25
$-68.6M
$5.5M
Q3 25
$-90.7M
$39.5M
Q2 25
$-87.5M
$11.9M
Q1 25
$-151.7M
$-2.0M
Q4 24
$-34.3M
$-5.1M
Q3 24
$-11.7M
$3.8M
Q2 24
$-32.1M
$-4.6M
Q1 24
$-16.7M
$15.2M
FCF Margin
FIP
FIP
MIRM
MIRM
Q4 25
-47.8%
3.7%
Q3 25
-64.5%
29.7%
Q2 25
-71.6%
9.3%
Q1 25
-157.7%
-1.8%
Q4 24
-42.4%
-5.1%
Q3 24
-14.0%
4.2%
Q2 24
-37.9%
-5.9%
Q1 24
-20.3%
22.0%
Capex Intensity
FIP
FIP
MIRM
MIRM
Q4 25
45.9%
0.4%
Q3 25
47.2%
0.1%
Q2 25
67.3%
0.1%
Q1 25
68.6%
0.0%
Q4 24
32.5%
0.0%
Q3 24
31.1%
0.2%
Q2 24
17.2%
1.0%
Q1 24
15.6%
0.0%
Cash Conversion
FIP
FIP
MIRM
MIRM
Q4 25
Q3 25
13.66×
Q2 25
Q1 25
-0.71×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FIP
FIP

Power Revenues$45.9M32%
Rail Revenue$44.6M31%
Service Other$22.8M16%
Gas Revenues$15.3M11%
Roadside Services Revenues$11.5M8%
Rapauno$1.2M1%

MIRM
MIRM

Livmarli$106.4M71%
Bile Acid Medicines$42.5M29%

Related Comparisons